

UC Irvine

UC Irvine Previously Published Works

Title

Therapeutic vaccination using HPV 16 E7 to eradicate CIN3.

Permalink

<https://escholarship.org/uc/item/1kr0k6gp>

Journal

Journal of gynecologic oncology, 30(6)

ISSN

2005-0380

Author

Tewari, Krishnansu S

Publication Date

2019-11-01

DOI

10.3802/jgo.2019.30.e119

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

Editorial



Therapeutic vaccination using HPV 16 E7 to eradicate CIN3

Krishnansu S. Tewari

Division of Gynecologic Oncology, University of California, Irvine Medical Center, Irvine, CA, USA

OPEN ACCESS

Received: Sep 9, 2019

Accepted: Sep 9, 2019

Correspondence to

Krishnansu S. Tewari

Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of California, Irvine Medical Center, 333 City Blvd. West Suite 1400, Orange, CA 92868, USA.
E-mail: ktewari@uci.edu

Copyright © 2019. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID iDs

Krishnansu S. Tewari
<https://orcid.org/0000-0002-8417-7000>

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

► See the article “A phase 1/2a, dose-escalation, safety and preliminary efficacy study of oral therapeutic vaccine in subjects with cervical intraepithelial neoplasia 3” in volume 30, e88.

The cervical cancer epidemic continues with approximately 569,847 new cases and 311,394 deaths reported worldwide annually [1]. Unique among human malignancies, invasive disease is typically diagnosed between the ages of 35 and 44 years, when young children are in the home and patients are in the midst of their careers. While early stage carcinomas (up to 2018 International Federation of Gynecology and Obstetrics [FIGO] IB₁₋₂) can often be cured via radical surgery with lymphadenectomy and adjuvant therapy as indicated by surgico-pathologic findings, locally advanced disease (FIGO stages IB₃-IVA) lends itself to platinum-based chemoradiation followed by high dose rate intracavitary brachytherapy [2]. Patients with central, isolated recurrence following definitive radiotherapy may be salvaged through pelvic exenteration, but in the era of chemoradiation, local recurrences are often accompanied by distant failure. Integration of the fully humanized monoclonal antibody, bevacizumab, with chemotherapy doublets to sequester vascular endothelial growth factor and prevent tumor angiogenesis, confers a statistically significant and clinically meaningful survival benefit, which is modest at best [3]. Interestingly, despite having been studied in many solid tumors, bevacizumab has only demonstrated a survival advantage in cervical cancer, 2 (of 7) trials in colorectal cancer, and in a single study of unresectable pleural mesothelioma. Given that prevention of the development of invasive carcinoma will always be preferable to treatment, there has been renewed focus on precancerous lesions (e.g., cervical intraepithelial neoplasia [CIN] 3) which often require invasive surgical techniques to eradicate (e.g., surgical excision or ablation using cryotherapy or CO₂ laser).

The scientific advances in our understanding of cervical neoplasia can be traced back through the centuries beginning over 2000 years ago when Hippocrates the Asclepiad (460–375 BCE) of the Greek Island of Kos originally described the disease as being so destructive “it is better to be left uncured than treated” [4]. The Italian cancer epidemiologist and physician Domenico Antonio Rigoni-Stern (1810–1855) analyzed death certificates of women in Verona during the period of 1760–1839 and recorded a high frequency of cervical cancer in married women, widows, and prostitutes; rarely did the disease manifest in virgins and nuns [5]. Accordingly, he postulated that the disease may arise through sexual contact. Before his theory would be validated, another Greek physician, Georgios Nikolaou Papanicolaou (1883–1962) embarked on his own odyssey which brought him to Cornell University in New York where he developed cytologic screening for cervical cancer [6], perfecting the technique by

often practicing on Mrs. Andromahi Mavrogeni Papanicolaou. Following its introduction into clinical practice in the 1950s, the Pap smear has saved thousands of lives, further cementing the disease's novelty through cost-effective, non-invasive, reliable screening. Finally, from 1976–1984, the German virologist Harald zur Hausen (1936–) identified the etiologic role of human papillomavirus (HPV) subtypes 16 and 18 in the development of cervical cancer [7], leading directly to high risk HPV DNA detection assays to augment cytologic screening through increased sensitivity. zur Hausen would ultimately receive the Nobel Prize in Physiology or Medicine in 2008 for this discovery. Not only has the identification of relevant viral DNA sequences allowed for the development of prophylactic HPV vaccination using virus-like particle technology incorporating a cDNA of the highly antigenic L1 HPV capsid protein, but the molecular cascade which governs virus-induced carcinogenesis has also been elucidated. Specifically, the HPV oncoproteins E6 and E7 degrade and inactivate the cellular tumor suppressor gene products, p53 and pRb, respectively, leading directly to dysregulation of the cell cycle [8]. Inflamed tumors develop through infection by high risk HPV subtypes and viral integration into host DNA which disrupts the viral regulatory E2 reading frame, resulting in loss of the negative feedback loop which otherwise prevents viral oncogene expression. With continued understanding of the immunologic tolerance taking place in the tumor microenvironment, we are finally in a position to consider therapeutic vaccination for this disease based on HPV oncogene expression. In a randomized, placebo-controlled phase 2 trial involving 129 women with CIN2–3 using the HPV 16 E6 and E7-based therapeutic vaccine, tipapkinogen sovavivec, complete resolution among vaccine-recipients with CIN3 was 21% (compared to 0% in the placebo arm) [9].

In the September 2019 issue of the *Journal of Gynecologic Oncology*, Park and colleagues [10] have reported data from a phase 1/2a dose-escalation study of BLS-M07 to treat CIN3. The vaccine is novel and is orally administered five times each week (on weeks 1, 2, 4, and 8) at a dose of 1,000 mg. By embedding the HPV 16 E7 antigen on the surface of the *Lactobacillus casei* vaccine construct, the investigators were able to monitor disease regression using the Reid Colposcopic Index grading system and measure serum HPV 16 E7 antibody production. There were no grade 3 or 4 treatment-related adverse events or deaths observed among the 19 patients enrolled with CIN3. Importantly, not only did vaccination induce protective humoral immunity, but in phase 2a, six of eight subjects (75%) were cured at 16 weeks' follow-up [10]. This contrasts favorably with what is observed in clinical practice during which time regression rates of 25% may require up to 1 year or even longer.

The oral schedule, high efficacy, absence of notable side effects, and position during the preinvasive course of the disease represent clear advantages of this vaccine strategy. However, because the trial was not placebo-controlled and the investigators performing colposcopic-directed biopsies after vaccination may not have been blinded to the participation by the patients on the trial, the efficacy results will need further validation in a double-randomized, placebo-controlled trial. In addition, in designing a confirmatory trial, a strong consideration for excisional biopsy (cold knife cervical conization or large loop excision of the transformation zone) should be made so as to pathologically confirm complete tumor regression induced by recipients of study vaccine. A revision of the administration schedule to fewer days and/or fewer weeks may have a positive impact on compliance in a real world setting, provided that efficacy is not compromised. Finally, applicability of this novel technology to patients with non-HPV 16 CIN3 along with analysis of viral DNA clearance through hybrid capture will also need to be addressed.

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018;68:394-424.
[PUBMED](#) | [CROSSREF](#)
2. Tewari KS, Monk BJ. Evidence-based treatment paradigms for management of invasive cervical carcinoma. *J Clin Oncol*. Forthcoming 2019.
[PUBMED](#) | [CROSSREF](#)
3. Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. *N Engl J Med* 2014;370:734-43.
[PUBMED](#) | [CROSSREF](#)
4. Karamperopoulos D, Kouzis A. Cancer in ancient Greek physicians. Athens: Stamoulis; 1902.
5. Rigoni-Stern DA. Statistical facts related to cancerous diseases. *G Serv Progress Patologia Terapia* 1842;2:507-17.
6. Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. *Am J Obstet Gynecol* 1941;42:193-206.
[CROSSREF](#)
7. Dürst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. *Proc Natl Acad Sci U S A* 1983;80:3812-5.
[PUBMED](#) | [CROSSREF](#)
8. Tewari KS, Taylor JA, Liao SY, DiSaia PJ, Burger RA, Monk BJ, et al. Development and assessment of a general theory of cervical carcinogenesis utilizing a severe combined immunodeficiency murine-human xenograft model. *Gynecol Oncol* 2000;77:137-48.
[PUBMED](#) | [CROSSREF](#)
9. Harper DM, Nieminen P, Donders G, Einstein MH, Garcia F, Huh WK, et al. The efficacy and safety of tipapkinogen sovavivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up. *Gynecol Oncol* 2019;153:521-9.
[PUBMED](#) | [CROSSREF](#)
10. Park YC, Ouh YT, Sung MH, Park HG, Kim TJ, Cho CH, et al. A phase 1/2a, dose-escalation, safety and preliminary efficacy study of oral therapeutic vaccine in subjects with cervical intraepithelial neoplasia 3. *J Gynecol Oncol* 2019;30:e88.
[CROSSREF](#)